What are the key takeaways from this The Bio Report episode?

Key insights include: **Early detection window:** Alpha sheet toxic oligomers form 10–30 years before Alzheimer's symptoms appear, making them detectable far earlier than amyloid plaques visible on PET imaging. AltPep's blood-based SOBA assay has retrospectively identified disease in banked samples up to 16 years before clinical onset, opening a treatment window current diagnostics cannot access.; **Structural targeting vs. antibody limitations:** Existing FDA-approved antibody therapies bind 3–5 amino acid surface epitopes, making them unable to distinguish toxic oligomers from benign amyloid forms. AltPep's synthetic peptides target alpha sheet structure directly, achieving nanomolar binding selectivity — enabling the same compound to function as both a diagnostic capture agent and a therapeutic neutralizer.; **Intranasal therapeutic delivery:** AltPep's SOBIN therapeutic is administered intranasally, allowing it to reach diffusing toxic oligomers in the brain. In transgenic mouse models, intranasal dosing over 12 months reduced plaque formation and improved learning and memory — without binding plaques directly — by stimulating microglial clearance of upstream oligomers.

What did Valerie Daggett discuss on The Bio Report?

Valerie Daggett, founder and CEO of AltPep, explains how her company targets alpha sheet toxic oligomers — structural precursors to Alzheimer's plaques detectable up to 16 years before symptoms — using synthetic peptides designed to both diagnose and neutralize these early-stage disease triggers. Key topics include: **Early detection window:** Alpha sheet toxic oligomers form 10–30 years before Alzheimer's symptoms appear, making them detectable far earlier than amyloid plaques visible on PET imaging. AltPep's blood-based SOBA assay has retrospectively identified disease in banked samples up to 16 years before clinical onset, opening a treatment window current diagnostics cannot access.; **Structural targeting vs. antibody limitations:** Existing FDA-approved antibody therapies bind 3–5 amino acid surface epitopes, making them unable to distinguish toxic oligomers from benign amyloid forms. AltPep's synthetic peptides target alpha sheet structure directly, achieving nanomolar binding selectivity — enabling the same compound to function as both a diagnostic capture agent and a therapeutic neutralizer..

How long is this episode of The Bio Report?

This episode is 29 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Bio Report

An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages

January 7, 2026

29 min episode · 2 min read

Valerie Daggett

Episode

29 min

Read time

2 min

Topics

Startups, Leadership, Design & UX

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓Early detection window: Alpha sheet toxic oligomers form 10–30 years before Alzheimer's symptoms appear, making them detectable far earlier than amyloid plaques visible on PET imaging. AltPep's blood-based SOBA assay has retrospectively identified disease in banked samples up to 16 years before clinical onset, opening a treatment window current diagnostics cannot access.
✓Structural targeting vs. antibody limitations: Existing FDA-approved antibody therapies bind 3–5 amino acid surface epitopes, making them unable to distinguish toxic oligomers from benign amyloid forms. AltPep's synthetic peptides target alpha sheet structure directly, achieving nanomolar binding selectivity — enabling the same compound to function as both a diagnostic capture agent and a therapeutic neutralizer.
✓Intranasal therapeutic delivery: AltPep's SOBIN therapeutic is administered intranasally, allowing it to reach diffusing toxic oligomers in the brain. In transgenic mouse models, intranasal dosing over 12 months reduced plaque formation and improved learning and memory — without binding plaques directly — by stimulating microglial clearance of upstream oligomers.
✓Companion diagnostic as trial tool: SOBA functions as a mechanism-linked biomarker, tracking toxic oligomer burden in blood the way tumor burden is tracked in oncology. In animal studies, SOBIN treatment produced measurable drops in SOBA readings, enabling patient stratification, target confirmation, and treatment monitoring within a single integrated platform.
✓Platform extensibility across 14 amyloid diseases: AltPep has confirmed alpha sheet structure in 14 amyloid protein systems, including alpha-synuclein in Parkinson's, transthyretin in cardiac amyloidosis, and islet amyloid polypeptide in type 2 diabetes — the largest amyloid disease by patient count. The same SOBA assay detects all variants, using conventional antibodies only to identify which protein was captured.

What It Covers

Valerie Daggett, founder and CEO of AltPep, explains how her company targets alpha sheet toxic oligomers — structural precursors to Alzheimer's plaques detectable up to 16 years before symptoms — using synthetic peptides designed to both diagnose and neutralize these early-stage disease triggers.

Key Questions Answered

•Early detection window: Alpha sheet toxic oligomers form 10–30 years before Alzheimer's symptoms appear, making them detectable far earlier than amyloid plaques visible on PET imaging. AltPep's blood-based SOBA assay has retrospectively identified disease in banked samples up to 16 years before clinical onset, opening a treatment window current diagnostics cannot access.
•Structural targeting vs. antibody limitations: Existing FDA-approved antibody therapies bind 3–5 amino acid surface epitopes, making them unable to distinguish toxic oligomers from benign amyloid forms. AltPep's synthetic peptides target alpha sheet structure directly, achieving nanomolar binding selectivity — enabling the same compound to function as both a diagnostic capture agent and a therapeutic neutralizer.
•Intranasal therapeutic delivery: AltPep's SOBIN therapeutic is administered intranasally, allowing it to reach diffusing toxic oligomers in the brain. In transgenic mouse models, intranasal dosing over 12 months reduced plaque formation and improved learning and memory — without binding plaques directly — by stimulating microglial clearance of upstream oligomers.
•Companion diagnostic as trial tool: SOBA functions as a mechanism-linked biomarker, tracking toxic oligomer burden in blood the way tumor burden is tracked in oncology. In animal studies, SOBIN treatment produced measurable drops in SOBA readings, enabling patient stratification, target confirmation, and treatment monitoring within a single integrated platform.
•Platform extensibility across 14 amyloid diseases: AltPep has confirmed alpha sheet structure in 14 amyloid protein systems, including alpha-synuclein in Parkinson's, transthyretin in cardiac amyloidosis, and islet amyloid polypeptide in type 2 diabetes — the largest amyloid disease by patient count. The same SOBA assay detects all variants, using conventional antibodies only to identify which protein was captured.

Notable Moment

Daggett describes injecting pure alpha sheet toxic oligomers into the brains of healthy, non-transgenic mice and successfully inducing Alzheimer's-like cognitive and behavioral symptoms — then reversing those effects with intranasal SOBIN delivery, providing direct causal evidence that these oligomers trigger the disease rather than merely correlate with it.

Know someone who'd find this useful?

No transcript yet — request it by email, free

We'll transcribe this episode on request and email you the full transcript and AI summary — usually within a day. No account needed.

One email, no spam. We’ll also show you what SignalCast does.